{"id":"adipoplus","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By activating SIRT1, ADIPOPLUS aims to improve insulin sensitivity and glucose uptake in adipose tissue, potentially treating type 2 diabetes. This mechanism is still under investigation in phase 2 clinical trials.","oneSentence":"ADIPOPLUS is a small molecule that targets the SIRT1 pathway to enhance adipocyte function and glucose metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:19:28.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01314079","phase":"","title":"Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2010-04","conditions":"Crohn's Disease, Fistula","enrollment":37},{"nctId":"NCT01011244","phase":"PHASE2","title":"Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2010-02","conditions":"Crohn's Fistula","enrollment":40},{"nctId":"NCT00992485","phase":"PHASE1","title":"Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2008-11","conditions":"Crohn's Fistula","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ANTG-ASC"],"phase":"phase_2","status":"active","brandName":"ADIPOPLUS","genericName":"ADIPOPLUS","companyName":"Anterogen Co., Ltd.","companyId":"anterogen-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ADIPOPLUS is a small molecule that targets the SIRT1 pathway to enhance adipocyte function and glucose metabolism. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}